Insider Transactions Reported by 15 Insiders of Vanda Pharmaceuticals Inc.

Symbol: VNDA on Nasdaq
Location: Washington, DC

Quick Takeaways

VNDA - Vanda Pharmaceuticals Inc. has 15 insiders with reported activity on this page.
Net insider value flow over the last year: -$2,686,931.
Recent transaction rows are available for direct filing-level review.

What Changed

Buy value: $169,967; sell value: $2,856,897.
Net share flow: -311,342.

Why This Matters

This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.

Source Evidence

Filed on Form 4

Issuer insider activity is sourced from SEC Forms 3, 4, and 5.

See Original Filing

Insider trading overview

Last 12 months

Net insider flow leans to selling over the last 12 months. Net value: -$2,686,931.

Buys

$169,967

Shares: 40,000

Insiders: 1

Sells

$2,856,898

Shares: 351,342

Insiders: 7

Net

-$2,686,931

Shares: -311,342

Insiders: -6

Window (months)	Buy shares	Sell shares	Buy $	Sell $	Net $
0-3	0	344,342	$0	$2,824,768	-$2,824,768
3-6	0	0	$0	$0	$0
6-9	10,000	0	$41,500	$0	+$41,500
9-12	30,000	7,000	$128,467	$32,130	+$96,337

Vanda Pharmaceuticals Inc. executives and other stock owners filed with the SEC include:

Name	Relationship	Holdings Value	Past Year Net Change	Change %	Valuation	Report Date
Mihael H. Polymeropoulos	President and CEO, Director, Chairman of the Board	$22,104,927	-$1,107,004	-4.8%	Filing P/S	02 Mar 2026
Gunther Birznieks	SVP, Business Development	$4,084,982	-$350,730	-7.9%	Filing P/S	02 Mar 2026
Kevin Patrick Moran	SVP, CFO & Treasurer	$3,405,231	-$350,821	-9.3%	Mixed	02 Mar 2026
Timothy Williams	SVP & General Counsel	$3,119,963	-$350,755	-10%	Filing P/S	02 Mar 2026
Joakim Wijkstrom	SVP, Chief Marketing Officer	$2,756,421	-$254,590	-8.5%	Filing P/S	02 Mar 2026
Christos Vasilios Mihael Polymeropoulos	Senior VP, Medical Director	$863,750			Median	01 Apr 2026
Scott Laverne Howell	VP and Chief People Officer	$757,474			Median	01 Apr 2026
Tage Honore	Director	$750,556	-$240,900	-24%	Filing P/S	23 Feb 2026
Richard W. Dugan	Director	$700,943			Mixed	05 Jun 2025
Phaedra Chrousos	Director	$487,232			Mixed	05 Jun 2025
Aranthan S. Jones II	Chief Corp. Affairs Officer	$478,763			Mixed	15 Sep 2021
Anne Sempowski Ward	Director	$470,314			Mixed	05 Jun 2025
Stephen Ray Mitchell	Director	$445,606	-$32,130	-6.7%	Filing P/S	13 Jun 2025
Charles Cliff Duncan	Director	$394,573			Median	22 Apr 2026
Thomas Watkins	Director	$368,294			Mixed	02 Jun 2022

Top shareholders of Vanda Pharmaceuticals Inc. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
BlackRock, Inc.	13F 13D/G	Company	8.1% from 13D/G	7,773,535	$68,562,579	—	31 Dec 2025	13F 13D/G
VANGUARD GROUP INC	13F	Company	6.3%	3,731,851	$32,914,925	—	31 Dec 2025	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	5.7%	3,380,961	$29,820,076	—	31 Dec 2025	13F
BlackRock Portfolio Management LLC	13D/G	—	5.5%	3,251,563	$28,678,786	-$10,826,753	31 Dec 2025	13D/G
Mihael H. Polymeropoulos	3/4/5	President and CEO, Director, Chairman of the Board	4.6%	2,704,496	$22,104,927	-$1,107,004	02 Mar 2026	3/4/5
ACADIAN ASSET MANAGEMENT LLC	13F	Company	4.1%	2,410,414	$21,253,000	—	31 Dec 2025	13F
DIMENSIONAL FUND ADVISORS LP	13F	Company	3.6%	2,118,428	$18,682,439	—	31 Dec 2025	13F
AIGH Capital Management LLC	13F	Company	3.4%	1,998,431	$17,626,162	—	31 Dec 2025	13F
MILLENNIUM MANAGEMENT LLC	13F 13D/G	Company	2.8% from 13D/G	1,679,013	$14,808,895	—	31 Dec 2025	13F 13D/G
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	2.4%	1,391,790	$12,278,432	—	31 Dec 2025	13F
STATE STREET CORP	13F	Company	2.1%	1,263,539	$11,144,414	—	31 Dec 2025	13F
Krensavage Asset Management, LLC	13F	Company	2%	1,180,388	$10,411,000	—	31 Dec 2025	13F
Empire Financial Management Company, LLC	13F	Company	1.9%	1,108,245	$9,774,720	—	31 Dec 2025	13F
TWO SIGMA ADVISERS, LP	13F	Company	1.8%	1,049,300	$9,254,826	—	31 Dec 2025	13F
TWO SIGMA INVESTMENTS, LP	13F	Company	1.7%	978,990	$8,634,692	—	31 Dec 2025	13F
Connor, Clark & Lunn Investment Management Ltd.	13F	Company	1.3%	743,546	$6,558,076	—	31 Dec 2025	13F
JACOBS LEVY EQUITY MANAGEMENT, INC	13F	Company	1.2%	708,428	$6,248,335	—	31 Dec 2025	13F
AQR CAPITAL MANAGEMENT LLC	13F	Company	1.1%	627,006	$5,530,194	—	31 Dec 2025	13F
MORGAN STANLEY	13F	Company	1%	593,023	$5,230,464	—	31 Dec 2025	13F
FEDERATED HERMES, INC.	13F	Company	0.94%	554,427	$4,890,047	—	31 Dec 2025	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.85%	500,515	$4,414,542	—	31 Dec 2025	13F
Jump Financial, LLC	13F	Company	0.8%	473,800	$4,178,916	—	31 Dec 2025	13F
Gunther Birznieks	3/4/5	SVP, Business Development	0.84%	494,197	$4,084,982	-$350,730	02 Mar 2026	3/4/5
NORTHERN TRUST CORP	13F	Company	0.73%	429,113	$3,784,777	—	31 Dec 2025	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.69%	408,342	$3,601,577	—	31 Dec 2025	13F
JPMORGAN CHASE & CO	13F	Company	0.67%	396,017	$3,492,870	—	31 Dec 2025	13F
Kevin Patrick Moran	3/4/5	SVP, CFO & Treasurer	0.7%	412,015	$3,405,231	-$350,821	02 Mar 2026	3/4/5
Timothy Williams	3/4/5	SVP & General Counsel	0.64%	377,450	$3,119,963	-$350,755	02 Mar 2026	3/4/5
Joakim Wijkstrom	3/4/5	SVP, Chief Marketing Officer	0.56%	333,469	$2,756,421	-$254,590	02 Mar 2026	3/4/5
Nuveen, LLC	13F	Company	0.49%	291,473	$2,570,792	—	31 Dec 2025	13F
Quantinno Capital Management LP	13F	Company	0.44%	261,802	$2,309,094	—	31 Dec 2025	13F
KENNEDY CAPITAL MANAGEMENT LLC	13F	Company	0.4%	235,169	$2,074,191	—	31 Dec 2025	13F
FMR LLC	13F	Company	0.38%	222,269	$1,960,413	—	31 Dec 2025	13F
Trexquant Investment LP	13F	Company	0.35%	204,491	$1,803,611	—	31 Dec 2025	13F
Monaco Asset Management SAM	13F	Company	0.33%	196,286	$1,731,243	—	31 Dec 2025	13F
BARCLAYS PLC	13F	Company	0.32%	191,036	$1,684,938	—	31 Dec 2025	13F
SUSQUEHANNA INTERNATIONAL GROUP, LLP	13F	Company	0.32%	190,622	$1,681,286	—	31 Dec 2025	13F
SEI INVESTMENTS CO	13F	Company	0.32%	190,261	$1,678,102	—	31 Dec 2025	13F
WELLINGTON MANAGEMENT GROUP LLP	13F	Company	0.3%	178,851	$1,577,466	—	31 Dec 2025	13F
Janney Montgomery Scott LLC	13F	Company	0.3%	175,541	$1,548,000	—	31 Dec 2025	13F
Bank of New York Mellon Corp	13F	Company	0.29%	171,670	$1,514,130	—	31 Dec 2025	13F
CITIGROUP INC	13F	Company	0.26%	152,491	$1,344,970	—	31 Dec 2025	13F
STATE OF WISCONSIN INVESTMENT BOARD	13F	Company	0.25%	150,542	$1,327,780	—	31 Dec 2025	13F
Susquehanna Portfolio Strategies, LLC	13F	Company	0.25%	150,427	$1,326,766	—	31 Dec 2025	13F
AMERICAN CENTURY COMPANIES INC	13F	Company	0.25%	150,419	$1,326,696	—	31 Dec 2025	13F
GSA CAPITAL PARTNERS LLP	13F	Company	0.25%	148,757	$1,312,000	—	31 Dec 2025	13F
Squarepoint Ops LLC	13F	Company	0.23%	135,839	$1,198,100	—	31 Dec 2025	13F
KLP KAPITALFORVALTNING AS	13F	Company	0.23%	135,400	$1,194,228	—	31 Dec 2025	13F
UBS Group AG	13F	Company	0.21%	124,665	$1,099,545	—	31 Dec 2025	13F
Invesco Ltd.	13F	Company	0.21%	122,995	$1,084,816	—	31 Dec 2025	13F

Recent Insider Transactions by Companies or Individuals for Vanda Pharmaceuticals Inc.

Showing up to 300 most recent insider transactions from the last 12 months.

Insider	Symbol	Class	Transaction	%	Value $	* Price $	Shares	Shares Owned	Date	Ownership
Charles Cliff Duncan	VNDA	Common Stock	Award				57,101	57,101	22 Apr 2026	Direct
Timothy Williams	VNDA	Common Stock	Sale	-10.1%	$350,755	$8.27	-42,434	377,450	02 Mar 2026	Direct
Kevin Patrick Moran	VNDA	Common Stock	Sale	-9.35%	$350,821	$8.27	-42,442	411,380	02 Mar 2026	Direct
Joakim Wijkstrom	VNDA	Common Stock	Sale	-8.46%	$254,590	$8.27	-30,800	333,469	02 Mar 2026	Direct
Mihael H. Polymeropoulos	VNDA	Common Stock	Sale	-5.46%	$1,276,971	$8.17	-156,235	2,704,496	02 Mar 2026	Direct
Gunther Birznieks	VNDA	Common Stock	Sale	-7.91%	$350,730	$8.27	-42,431	494,197	02 Mar 2026	Direct
Tage Honore	VNDA	Common Stock	Sale	-24.3%	$240,900	$8.03	-30,000	93,469	23 Feb 2026	Direct
Joakim Wijkstrom	VNDA	Common Stock	Award	52.2%			125,000	364,269	18 Feb 2026	Direct
Gunther Birznieks	VNDA	Common Stock	Award	30.4%			125,000	536,628	18 Feb 2026	Direct
Timothy Williams	VNDA	Common Stock	Award	42.4%			125,000	419,884	18 Feb 2026	Direct
Kevin Patrick Moran	VNDA	Common Stock	Award	38%			125,000	453,822	18 Feb 2026	Direct
Mihael H. Polymeropoulos	VNDA	Common Stock	Award	22.5%			525,000	2,860,731	18 Feb 2026	Direct
Mihael H. Polymeropoulos	VNDA	Common Stock	Purchase	0.43%	$41,500	$4.15	10,000	2,335,731	07 Aug 2025	Direct
Stephen Ray Mitchell	VNDA	Common Stock	Sale	-6.73%	$32,130	$4.59	-7,000	97,082	13 Jun 2025	Direct
Stephen Ray Mitchell	VNDA	Common Stock	Award	132%			59,225	104,082	05 Jun 2025	Direct
Phaedra Chrousos	VNDA	Common Stock	Award	92.4%			59,225	123,350	05 Jun 2025	Direct
Richard W. Dugan	VNDA	Common Stock	Award	50.1%			59,225	177,454	05 Jun 2025	Direct
Tage Honore	VNDA	Common Stock	Award	92.2%			59,225	123,469	05 Jun 2025	Direct
Anne Sempowski Ward	VNDA	Common Stock	Award	99%			59,225	119,067	05 Jun 2025	Direct
Mihael H. Polymeropoulos	VNDA	Common Stock	Purchase	0.43%	$43,995	$4.40	10,000	2,325,731	21 May 2025	Direct
Mihael H. Polymeropoulos	VNDA	Common Stock	Purchase	0.87%	$84,472	$4.22	20,000	2,315,731	16 May 2025	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.